Join Cassie Dolecki, PharmD, a Clinical Pharmacy Specialist in Rheumatology at Allegheny Health Network in Pittsburgh, Pennsylvania, as she explores the real-world effectiveness of Guselkumab in the management of psoriatic arthritis.

This discussion highlights recent findings from the CorEvitas Psoriatic Arthritis and Spondyloarthritis Registry, which assessed six-month persistence and effectiveness rates in adult PsA patients. The study revealed that nearly 80% of patients continued Guselkumab treatment over six months, experiencing significant improvements in disease activity, including joint symptoms, skin manifestations, and patient-reported pain.

Cassie also examines how these findings align with phase three clinical trial data, including DISCOVER-1, DISCOVER-2, and COSMOS trials, where Guselkumab demonstrated high retention rates among patients with active PsA, including those who had previously failed TNF inhibitors. Additionally, she reviews a retrospective study from Spain that found high persistence rates at two years in patients using Guselkumab for PsA or psoriasis in clinical practice.

The discussion underscores Guselkumab’s consistent efficacy in treating psoriatic arthritis both in controlled trials and real-world settings.

For more expert insights on PsA management and biologic therapies, visit RhAPP.org and explore the RhAPP ACE App for the latest updates.